Source link : https://www.newshealth.biz/health-news/investigational-treatment-promising-for-sord-deficiency/
MONTREAL — An investigational oral aldose reductase inhibitor, govorestat, significantly improved primary outcomes of physical function and serum sorbitol reduction in patients with sorbitol dehydrogenase (SORD) deficiency, the interim results of the phase 3 INSPIRE trial showed. At the 12-month point of the 24-month prospective trial, patients randomly assigned to receive daily govorestat 20 mg/kg […]
Author : News Health
Publish date : 2024-07-04 10:49:47
Copyright for syndicated content belongs to the linked Source.
Categories